Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?
- 1 November 2014
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 42 (3), 397-408
- https://doi.org/10.1007/s00259-014-2938-9
Abstract
To investigate whether MRI (RECIST 1.1, WHO criteria and the volumetric approach) or 18F-FDG PET/CT (PERCIST 1.0) are able to predict long-term outcome in nonsurgical patients with giant cell tumour of the tendon sheath or of the diffuse type (GCT-TS/DT).This publication has 39 references indexed in Scilit:
- Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinibClinical Sarcoma Research, 2013
- Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitisCancer, 2011
- Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- FDG Uptake in Giant Cell Tumor of the Tendon Sheath in a Patient Restaged for Gastrointestinal Stroma Tumor (GIST)Clinical Nuclear Medicine, 2009
- PET, CT, and MR Imaging of Extra-articular Pigmented Villonodular SynovitisClinical Nuclear Medicine, 2007
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and MetastasisCell, 2006
- FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistanceOncogene, 2005
- Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibBlood, 2005
- The Hallmarks of CancerCell, 2000